Drug Resistance Reversal Potential of Ursolic Acid Derivatives against Nalidixic Acid‐ and Multidrug‐resistant Escherichia coli
暂无分享,去创建一个
Feroz Khan | Santosh Kumar Srivastava | D. Yadav | Mahendra P Darokar | F. Khan | S. Srivastava | G. Dwivedi | Anupam Maurya | M. Darokar | Dharmendra Kumar Yadav | Gaurav Raj Dwivedi | Anupam Maurya | S. K. Srivastava | Dharmendra K. Yadav | Mahendra P. Darokar | S. Srivastava
[1] L. Piddock. Multidrug-resistance efflux pumps ? not just for resistance , 2006, Nature Reviews Microbiology.
[2] B. Marquez. Bacterial efflux systems and efflux pumps inhibitors. , 2005, Biochimie.
[3] N. Goel,et al. A ten year analysis of multi-drug resistant blood stream infections caused by Escherichia coli & Klebsiella pneumoniae in a tertiary care hospital , 2012, The Indian journal of medical research.
[4] J. Molnár,et al. New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. , 2008, Current drug targets.
[5] F. Mozzi,et al. Applied Microbial and Cell Physiology , 2022 .
[6] Jonathan R Edwards,et al. Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] A. Driessen,et al. Distribution and Physiology of ABC-Type Transporters Contributing to Multidrug Resistance in Bacteria , 2007, Microbiology and Molecular Biology Reviews.
[8] L. Amaral,et al. Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. , 2010, Methods in molecular biology.
[9] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[10] Brad Spellberg,et al. The future of antibiotics and resistance. , 2013, The New England journal of medicine.
[11] J. Gertsch,et al. Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. , 2011, Planta medica.
[12] J. Pagés,et al. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. , 2009, Biochimica et biophysica acta.
[13] I. T. Babalola,et al. Ubiquitous Ursolic Acid: A Potential Pentacyclic Triterpene Natural Product , 2013 .
[14] S. Kumar. Properties of adenyl cyclase and cyclic adenosine 3',5'-monophosphate receptor protein-deficient mutants of Escherichia coli , 1976, Journal of bacteriology.
[15] L. Amaral,et al. Identification of efflux-mediated multi-drug resistance in bacterial clinical isolates by two simple methods. , 2010, Methods in molecular biology.
[16] S. Gibbons. Plants as a Source of Bacterial Resistance Modulators and Anti-Infective Agents , 2005, Phytochemistry Reviews.
[17] N. Koyama,et al. Cloning, sequencing and functional expression in Escherichia coli of the gene for a P-type Na(+)-ATPase of a facultatively anaerobic alkaliphile, Exiguobacterium aurantiacum. , 2005, Biochimica et biophysica acta.
[18] D. Méhn,et al. Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. , 2008, Expert opinion on drug metabolism & toxicology.
[19] P. de Mol,et al. Antimicrobial Resistance and Spread of Multi Drug Resistant Escherichia coli Isolates Collected from Nine Urology Services in the Euregion Meuse-Rhine , 2012, PloS one.
[20] Hiroshi Nikaido,et al. Efflux-Mediated Drug Resistance in Bacteria , 2012, Drugs.
[21] Yanmin Hu,et al. Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies. , 2013, The Journal of antimicrobial chemotherapy.
[22] J. Molnár,et al. Inducement and Reversal of Tetracycline Resistance in Escherichia coli K-12 and Expression of Proton Gradient-Dependent Multidrug Efflux Pump Genes , 2005, Antimicrobial Agents and Chemotherapy.
[23] P. Hawkey,et al. The changing epidemiology of resistance. , 2009, The Journal of antimicrobial chemotherapy.
[24] Atul Gupta,et al. QSAR and docking studies on chalcone derivatives for antitubercular activity against M. tuberculosis H37Rv , 2014 .
[25] S. Srivastava,et al. Antibacterial and Synergy of Clavine Alkaloid Lysergol and its Derivatives Against Nalidixic Acid‐Resistant Escherichia coli , 2013, Chemical biology & drug design.
[26] D. Bernhard,et al. Ursolic acid causes DNA-damage, p53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. , 2011, Atherosclerosis.
[27] J. Pagés,et al. Antibiotic Stress, Genetic Response and Altered Permeability of E. coli , 2007, PloS one.
[28] Brad Spellberg,et al. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] K. Lewis,et al. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[30] I. Chopra,et al. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections , 2010, Nature Reviews Microbiology.
[31] Debprasad Chattopadhyay,et al. A potent sperm motility-inhibiting activity of bioflavonoids from an ethnomedicine of Onge, Alstonia macrophylla Wall ex A. DC, leaf extract. , 2005, Contraception.
[32] H. Nikaido. Multidrug resistance in bacteria. , 2009, Annual review of biochemistry.
[33] M. Hassani. The Crisis of Resistant Gram- Negative Bacterial Infections: Is there any Hope for ESKAPE? , 2014 .
[34] Katsunori Tanaka,et al. Cytotoxic Activity of Ursolic Acid Derivatives Obtained by Isolation and Oxidative Derivatization , 2013, Molecules.
[35] G. Eliopoulos,et al. Antimicrobial Activity of Quinupristin-Dalfopristin Combined with Other Antibiotics against Vancomycin-Resistant Enterococci , 2002, Antimicrobial Agents and Chemotherapy.
[36] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .
[37] V. Chaturvedi,et al. Bioenhancing and antimycobacterial agents from Ammannia multiflora. , 2012, Planta medica.
[38] A. Yamaguchi,et al. Novel Macrolide-Specific ABC-Type Efflux Transporter inEscherichia coli , 2001, Journal of bacteriology.
[39] L. Piddock,et al. The Efflux Pump Inhibitor Reserpine Selects Multidrug-Resistant Streptococcus pneumoniae Strains That Overexpress the ABC Transporters PatA and PatB , 2008, Antimicrobial Agents and Chemotherapy.
[40] Feroz Khan,et al. QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase‐I , 2013 .
[41] Ashwani Kumar,et al. Piperine, a Phytochemical Potentiator of Ciprofloxacin against Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.
[42] J. P. Sharma,et al. Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus. , 2012, The Journal of antimicrobial chemotherapy.
[43] M. Argyres,et al. Hospital-acquired infections due to gram-negative bacteria. , 2010, The New England journal of medicine.
[44] F. Khan,et al. 4‐Hydroxy‐α‐Tetralone and its Derivative as Drug Resistance Reversal Agents in Multi Drug Resistant Escherichia coli , 2014, Chemical biology & drug design.
[45] J. Ruiloba. [Antimicrobial combinations]. , 1972, Gaceta medica de Mexico.
[46] D. Livermore. Has the era of untreatable infections arrived? , 2009, The Journal of antimicrobial chemotherapy.